IGFBP3 Enhances Treatment Outcome and Predicts Favorable Prognosis in ABC-DLBCL

Table 4

Univariate and multivariate Cox regression analysis of PFS from GEO.

Variables	Univariate Cox			Multivariate Cox
	HR	95% CI		HR	95% CI
IGFBP3 expression (high vs low)	0.624	0.350–1.112	0.110	0.503	0.249–1.016	0.055
Age (>60 vs ≤60)	1.167	0.754–1.806	0.489
Sex (male vs female)	0.822	0.544–1.240	0.349
Stage (III + IV vs I + II)	2.372	1.503–3.744	<0.001	1.005	0.420–2.407	0.990
Extranodal infiltration (>1 vs ≤1)	2.314	1.495–3.582	<0.001	1.332	0.648–2.737	0.435
ECOG score (>1 vs ≤1)	2.252	1.429–3.549	<0.001	1.609	0.723–3.582	0.244
LDH (elevated vs normal)	1.482	0.918–2.390	0.107	1.348	0.145–0.831	0.017
IPI score (>2 vs ≤2)	3.209	1.840–5.598	<0.001	2.914	0.850–9.985	0.089
Treatment response (non-CR vs CR)	1.106	0.616–1.988	0.735

ECOG score, eastern cooperative oncology group score; LDH, lactate dehydrogenase; CR, complete response; non-CR, partial response, stable disease, progressive disease; bold, significant difference.